Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Cairo University (CU)

Status and phase: Completed; Phase 2; Phase 1

Conditions: Systemic Lupus Erythematosis

Treatments: Drug: Hydroxychloroquine; Drug: Hydrocortisone; Drug: Cyclophosphamide

Study type: Interventional

Funder types: Other

Identifiers

NCT02756546

BC (1016)

Details and patient eligibility

About

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adult systemic lupus erythematosis patients

Exclusion criteria

• Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 2 patient groups

Control

No Intervention group

Description:

Healthy volunteers

Patients

Active Comparator group

Description:

SLE patients further divided into mild and severe patients

Treatment:

Drug: Cyclophosphamide

Drug: Hydrocortisone

Drug: Hydroxychloroquine